Claims for Patent: 5,955,100

Summary for Patent: 5,955,100

Title:	Prodrugs their preparation and use as pharmaceuticals
Abstract:	Glycosyl-spacer-drugs compounds (prodrugs), their preparation and their use as pharmaceuticals are described.
Inventor(s):	Bosslet; Klaus (Marburg, DE), Czech; Jorg (Marburg, DE), Hoffmann; Dieter (Marburg-Elnhausen, DE), Kolar; Cenek (Marburg, DE), Tillequin; Fran.cedilla.ois (Paris, FR), Florent; Jean-Claude (Les Ulis, FR), Azoulay; Michel (Paris, FR), Monneret; Claude (Paris, FR), Jacquesy; Jean-Claude (Buxerolles, FR), Gesson; Jean-Pierre (Chansseneuil du Poitou, FR), Koch; Michel (La Celle Saint Cloud, FR)
Assignee:	Behringwerke Aktiengesellschaft (Marburg, DE) Laboratories Hoechst S/A (Paris-La Defense, FR)
Application Number:	08/449,021
Patent Claims:	1. A compound of the formula I in which glycosyl is a poly-, oligo- or monosaccharide which can be cleaved off enzymatically, W is an aromatic or heteroaromatic or aliphatic group with conjugated double bonds or an amino-acid derivative which cyclizes after elimination of the glycosyl radical, in which the substituents R are, independently or identically, H, methyl, methoxy, carboxyl, methyloxycarbonyl, CN, hydroxyl, nitro, fluorine, chlorine, bromine, sulfo, sulfamoyl or (C.sub.1-4)-alkylsulfamoyl and p is 0 or 1 n is an integer, X is O, NH, methyleneoxy, methyleneamino or methylene(C.sub.1-4)-alkylamino and Y is O or NH, and drug is a compound which is linked via a hydroxyl, amino or imino group and has a biological effect, except anthracyclines linked via a 3'-amino group when p=0. 2. A compound as claimed in claim 1, wherein W is an aromatic or heteroaromatic group or an aliphatic group with conjugated double bonds or an amino-acid derivative residue which cyclizes after elimination of the glycosyl radical and has 5-20 carbon atoms and 0-4 heteroatoms, where heteroatom means N, O or S, to which substituents can be bonded, and R, p, n, X, Y and drugs are as defined in claim 1. 3. A compound as claimed in claim 1, wherein W is a phenyl radical or a polysubstituted phenyl radical in which the substituents R are, independently or identically, H, methyl, methoxy, carboxyl, methyloxycarbonyl, CN, hydroxyl, nitro, fluorine, chlorine, bromine, sulfo, sulfamoyl or (C.sub.1-4) alkylsulfamoyl, n is 1 to 4 and p, X, Y and drugs are as defined in claim 1. 4. (Amended) A compound as claimed in claim 3, wherein W is a phenyl radical or a monosubstituted phenyl radical in which one of the substituents R is methoxy, methyloxycarbonyl, CN, hydroxyl, nitro, fluorine, chlorine, bromine, sulfo or sulfamoyl, and the others are hydrogen. 5. A compound as claimed in claim 1, wherein the drug is an anthracycline which is not linked by 3'-amino groups when p=0 . 6. A process for the preparation of a compound according to formula I in claim 1, which comprises reacting a phenyl glycoside of the formula II in which glycosyl is a poly-, oligo- or monosaccharide whose hydroxyl groups are free or protected by acetyl or mono-, di- or trihaloacetyl protective groups with halogen being fluorine or chlorine or by benzyl protective groups, W, R, p, n, X, and Y are as defined in claim 5, and Z is a reactive leaving group selected from the group consisting of chloride, bromide, azide [or] and N-succinimidoxy, with a drug as defined in claim 5 in the presence of an organic base selected from the group consisting of triethylamine, diisopropylethylamine and dimethylaminopyridine and a solvent selected from the group consisting of acetonitrile, dioxane, tetrahydrofuran, dichloromethane and dichloroethane to give a protected intermediate compound, and subsequently eliminating the protective groups by hydrolysis with an alkali metal hydroxide solution, an alkali metal carbonate, an alkali metal cyanide, barium oxide, piperidine or morpholine in the presence of methanol, ethanol or water, resulting in a compound of the formula I. 7. A compound selected from the group consisting of 4'-O-[4-(Alpha-D-glucopyranosyloxy)phenylaminocarbonyl]etoposide, 4'-O-[4-(beta-D-galactopyranoxyloxy)phenylaminocarbonyl]etoposide, 4'-O-[4-(beta-D-glucuronyloxy)phenylaminocarbonyl]etoposide, 4'-O-(beta-D-glucuronyloxy)-3-nitrobenzylaminocarbonyl]etoposide, 4'-O-[4'-(beta-D-glucuronyloxy)-3-chlorobenzylaminocarbonyl]etoposide, 1-N-[4-(beta-D-gluocuronyloxy)benzyloxycarbonyl]mitomycin C, 14-O-[4-(beta-D-glucuronyloxy)-3-nitrobenzylaminocarbonyl]doxorubicin, 4-O-[4-(beta-D-glucuronyloxy)benzylaminocarbonyl]4-hydroxy-N, N-bis(2-chloroethyl)aniline,4-O-[4-(beta-D-glucuronyloxy)benzylaminocarbon yl]terfenadine, 3'-O-[4-(beta-D-glucuronyloxy)benzylaminocarbonyl]terbutaline, 3'-O-[4-(beta-D-glucuronyloxy)benzylaminocarbonyl]fenoterol, 1"-O-[4-(beta-D-glucuronyloxy)benzylaminocarbonyl]salbutamol, 3-O-[4-(beta-D-glucuronyloxy)benzylaminocarbonyl]muscarine, 4'-O-[4-(beta-D-glucuronyloxy)benzylaminocarbonyl]oxyphenbutazone, 2-O-[4-(beta-D-glucuronyloxy)benzylaminocarbonyl]salicylic acid, N-[4-(beta-D-glucuronyloxy)benzyloxycarbonyl]diclofenac, N-[4-(beta-D-glucuronyloxy)benzyloxycarbonyl]flufenamic acid, 4-N-[4-(beta-D-glucuronyloxy)benzyloxycarbonyl]-4-methylaminophenazone, 7-N-[4-(beta-D-glucuronyloxy)benzyloxycarbonyl]theophylline, 1-N-[4(beta-D-glucuronyloxy)benzyloxycarbonyl]nifedipine, 4-(beta-D-glucuronyl)-3-nitrobenzyl 2-[1 -cyano-1-(N-4-trifluoromethylphenyl)carbamoyl]propen-1-yl carbonate, N-[4-(Alpha-D-galactopyranosyloxy-carbonylamino)benzyloxycarbonyl]doxorubi cin, 9-O-[4-beta-D-glucuronyloxy)-3-chlorobenzyloxycarbonyl)quinine and methyl 18-O-[3,5-dimethoxy4-[4-(beta-D-glucuronyloxy)-3-chlorobenzyloxycarbonyl]b enzoyl]reserpate. 8. A pharmaceutical composition for the treatment of diseases in which intracellular enzymes are released or made accessible by cell damage comprising an effective amount of a compound as claimed in claim 1 and a pharmaceutically acceptable carrier. 9. The composition as claimed in claim 8, wherein the pharmaceutically acceptable carrier protein. 10. The composition as claimed in claim 8, wherein the composition further comprises a compound which breaks multiple drug resistance. 11. The composition as claimed in claim 9, wherein the carrier protein is human serum albumin or human acid alpha-1 glycoprotein. 12. The composition as claimed in claim 10, wherein the compound which breaks up multiple drug resistance is cyclosporin A, R-verapamil, pentoxifylline or rapamycin. 13. A compound as claimed in claim 5 wherein the drug is doxorubicin, 4'-epidoxorubicin, or 4- or 4' deoxydoxorubicin. 14. A compound as claimed in claim 1 wherein the drug is selected from the group consisting of etoposides, N,N-bis(2-chloroethyl)4-hydroxyaniline, 4-hydroxycyclophosphamide, vindesine, vinblastine, vincristine, terfenadine, terbutaline, fenoterol, salbutamol, muscarine, oxyphenbutazone, salicylic acid, p-aminosalicyclic acid, 5-fluorouracil, 5-fluorouridine, 5-fluorocytidine, methotrexate, diclofenac, flufenamic acid, 4-methylaminophenazone, theophylline, nifedipine, mitomycin C, mitoxantrone, camptothecin, m-AMSA, taxol, nocodazole, colchicine, cyclophosphamide, rachelmycin, cisplatin, melphalan, bleomycin, nitrogen mustard, phosphoramide mustard, verrucarin A, neocarcinostatin, calicheamicin, dynemicin, esperamicin A, quercetin, genistein, erbstatin, tyrphostin, rohitukin derivative, retinoic acid, butyric acid, phorbol ester, DMSO, aclacinomycin, progesterone, buserelin, tamoxifen, mifepristone, onapristone, N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide, pyridinyloxazol-2-one, quinolyl-, isoquinolyloxazol-2-one, staurosporine, ethanolamine, verapamil, forskolin, 1,9-dideoxyforskolin, quinine, quinidine, reserpine, methyl 18-O-(3,5-dimethoxy4-hydroxybenzoyl)reserpate, lonidamine, buthionine-sulfoximin, diethyl dithiocarbamate, cyclosporin A, rapamycin, azathioprine, chlorambucil, hydroxycrotonamide derivateive 2, 15-deoxyspergualine, FK 506, ibuprofen, indomethacin, aspirin, sulfasalazine, penicillamine, chloroquine, dexamethasone, prednisolone, mefenamic acid, paracetamol, 4-aminophenazone, muskosine, orciprenaline, isoprenaline, amiloride, p-nitrophenyl guanidinobenzoate and their derivatives additionally substituted by one or more hydroxyl, amino or imino groups, where the drug already has a hydroxyl, amino or imino group. 15. A method for the treatment of diseases in which intracellular enzymes are released or are made accessible by cell damage which comprises administering to a host in need of said treatment a pharmaceutical composition as claimed in claim 8. 16. A method for the treatment of diseases in which intracellular enzymes are released or are made accessible by cell damage which comprises administering to a host in need of said treatment an effective amount of a compound of the formula I as claimed in claim 1.

Details for Patent 5,955,100

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2016-09-21
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2016-09-21
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2016-09-21
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2016-09-21